Introduction
Despite advances in early detection and efforts to establish new therapies, prostate cancer remains the second cause of tumor-related deaths in the Western world. Clinically localized prostate cancer is successfully treated by radical prostatectomy or radiotherapy. In contrast, advanced stages of the tumor, initially responsive to androgen ablation, eventually develop a therapy-refractory phenotype for which only palliative treatment is available.
Interleukin-6 (IL-6), a cytokine mostly involved in the modulation of immuno-and inflammatory responses, has a role also in the regulation of proliferation, apoptosis, angiogenesis and differentiation (Akira et al., 1993) . It is implicated in the development and progression of several types of tumors including that of prostate (Keller et al., 1996; Trikha et al., 2003) . After initial studies revealed increased IL-6 levels in sera from patients with therapy-resistant metastatic disease in the absence of infection (Twillie et al., 1995) , IL-6 role in tumor progression became a subject of in vitro and in vivo investigations. Correlation between IL-6 protein levels and more advanced stages of the disease and poor prognosis is now well established (Siegall et al., 1990; Siegsmund et al., 1994; Adler et al., 1999; Drachenberg et al., 1999; Nakashima et al., 2000; Giri et al., 2001; Hobisch et al., 2001) .
IL-6 binds to its specific receptor, IL-6 receptor alpha (IL-6Ra), an 80 kDa glycosylated transmembrane protein belonging to the cytokine receptor superfamily. The activated IL-6Ra interacts with gp130, a transmembrane common cytokine receptor that is able to transduce IL-6 signal mainly through the Janus kinase/signal transduction and activator of transcription (JAK/STAT) factor 3, phosphatidylinositol-3 kinase/Akt and mitogen-activated protein kinases (MAPK) pathways. To investigate the role of IL-6 in advanced prostate cancer, we used the LNCaP-IL-6 þ subline, derived from parental LNCaP cells cultured in the presence of 5 ng/ml of the cytokine . These IL-6-selected cells acquire a growth advantage compared to the control cells, LNCaP-IL-6À passaged at the same time in the absence of IL-6. Most importantly, LNCaP-IL-6 þ cells express and secrete the cytokine and, differently from parental and control cells, do not undergo growth inhibition when exposed to exogenous IL-6. IL-6 has a survival effect in various cancers Hodge et al., 2005) . However, understanding its role in apoptosis in prostate cancer is limited (Chung et al., 2000) . To build on the observed growth advantage of LNCaP-IL-6 þ cells, we have investigated the sensitivity of these cells to apoptosis compared to the IL-6-negative control cells. We show that endogenous IL-6, acting through an autocrine loop, protects LNCaP-IL-6 þ cells from apoptosis.
Disregulation of Bcl-2 family members is often implicated in the acquisition of resistance to apoptosis in malignant cell lines (Fadeel and Orrenius, 2005) . We previously demonstrated that LNCaP-IL-6 þ cells lack the proapoptotic Bax and overexpress the antiapoptotic Bcl-2 proteins compared to the control cells (Steiner et al., 2006) . We here considered another important regulator of apoptosis, myeloid cell leukemia 1 (Mcl-1) , originally identified as an early gene induced during differentiation of ML-1 myeloid leukemia cells (Kozopas et al., 1993; Craig, 2002) . Mcl-1's role in the regulation of cell death has been mostly investigated in myeloma cells in which it mediates the prosurvival action of IL-6 (Jourdan et al., 2003) . Altered expression of Mcl-1 in specimens from prostate cancer compared to those from normal, hyperplastic or prostate intraepithelial neoplasia (PIN) (Krajewski et al., 1995; Krajewska et al., 1996; Royuela et al., 2001) suggests an involvement of this gene also in prostate carcinogenesis. In this study, by applying the small interfering RNA (siRNA) technology and using the chimeric anti-IL-6 antibody CNTO 328, we highlight the importance of Mcl-1 in mediating survival activity of IL-6 in prostate cancer. We finally sought to uncover IL-6-activated signaling pathways involved in the regulation of this protein. In particular, we investigated the impact of blocking the extracellular signal-regulated kinase (ERK1/2) MAPK signaling pathway on Mcl-1 protein expression. Although ERK1/2 MAPK have been frequently associated with cellular proliferation, their role in promoting survival in different cellular models became recently evident (Rubinfeld and Seger, 2005; Sridhar et al., 2005; Yoon and Seger, 2006) . Phospho-ERK1/2 were previously shown to be overexpressed in LNCaP-IL-6 þ (Gioeli et al., 1999; Steiner et al., 2003) and Du145 prostate cancer cells (Shimada et al., 2002) and clinical specimens (Gioeli et al., 1999; Royuela et al., 2002) . We now demonstrate that inhibition of this pathway in LNCaP-IL-6 þ cells diminishes levels of Mcl-1, thus confirming its involvement in the regulation of apoptosis.
Results
LNCaP-IL-6 þ are less sensitive to apoptosis than control cells It was previously reported that addition of exogenous IL-6 does not affect the growth of LNCaP-IL-6 þ , whereas it induces a G 1 growth arrest in parental (LNCaP-ATCC) and control (LNCaP-IL-6À) cells (Hobisch et al., 2000 . We questioned whether exposure to the cytokine also induces a different apoptotic response in the two sublines. For this reason, the cells were exposed to 10 ng/ml of IL-6 and apoptosis was quantified 3 days later by measuring levels of cleaved cytokeratin 18 (CK18). CK18 is expressed and released by most types of carcinomas, including that of the prostate. In the case of apoptosis, soluble CK18 has been demonstrated to be a substrate for caspases (Kramer et al., 2004) . As shown in Figure 1 , exposure to the cytokine induced a 100 and 75% increase of apoptosis in parental and LNCaP-IL-6À cells, respectively, whereas no changes in cleaved CK18 levels were observed in IL-6-treated LNCaP-IL-6 þ cells.
To further examine resistance to an apoptotic stimulus, we exposed the cells to the ionophore A23187 that is known to induce calcium-triggered cell death (Hajnoczky et al., 2003; Orrenius et al., 2003) in both benign and malignant prostate cells including LNCaP (Kyprianou et al., 1988; Martikainen and Isaacs, 1990; Gong et al., 1995) . We show that LNCaP-IL-6À cells exposed for 2 days to 1 mM A23187, in the presence of 3% charcoal-stripped fetal calf serum (CS FCS), undergo about eightfold higher induction of apoptosis than LNCaP-IL-6 þ cells subjected to the same treatment (Figure 2 ). Consistent with this finding, protein levels of cleaved caspase-3, after treatment with 0.5 or 1 mM A23187, were detected by Western analyses only in LNCaP-IL-6À cells (Figure 3) . Different rates of A23187-induced apoptosis between the two cell lines were also observed by FACS analysis for externalized phosphatidylserine (Table 1 ). In comparison to LNCaP-IL-6À cells, LNCaP-IL-6 þ displayed less apoptotic cells after 48 h in the presence of the calcium ionophore. Taken together, these data show a reduced sensitivity to apoptosis of LNCaP-IL-6 þ compared to control cells.
Neutralization of IL-6 autocrine loop by CNTO 328 increases apoptosis of LNCaP-IL-6 þ cells We next tested whether neutralization of endogenous IL-6 increases apoptosis index of LNCaP-IL-6 þ cells. IL-6 and Mcl-1 in prostate cancer cell survival IT Cavarretta et al
To neutralize IL-6 activity, we utilized the chimeric anti-IL-6 antibody CNTO 328 (Li et al., 2005) at a concentration of 10 mg/ml. This concentration was selected as the most effective on the basis of previous results showing the effect of CNTO 328 in decreasing LNCaP-IL-6 þ cell viability (Steiner et al., 2006) . When exposed to CNTO 328 for 4 days in the absence of serum, LNCaP-IL-6 þ cells underwent apoptosis, whereas LNCaP-IL-6À cells were unaffected by the presence of the anti-IL-6 antibody ( Figure 4 ). In particular, cleaved CK18 levels released from LNCaP-IL-6 þ cells treated with CNTO 328 were 30% higher than those measured in supernatants from cells treated with equal amounts of human immunoglobin G (hIgG) control. CNTO 328 also increased A23187-induced apoptosis of LNCaP-IL-6 þ , although not significantly (data not shown). These data show that CNTO 328, in our experimental conditions, is able to render LNCaP-IL-6 þ cells more sensitive to apoptosis. Figure 6a , Mcl-1 signal dropped to almost undetectable levels after 1 day of exposure to 10 nM of the specific siRNA and remained low for at least 3 days. Mcl-1 levels in cells transfected with the negative control did not change at any time. An inhibitory effect of specific siRNA on Mcl-1 expression was seen also in control cells ( Figure 6b ). Cells were therefore transfected with 10 nM Mcl-1 siRNA or control siRNA, and cleaved CK18 was measured 2 days later. We found that apoptosis increased by about 60% in LNCaP-IL-6 þ cells after suppression of Mcl-1, whereas it did not change in the control cells ( Figure 6c ). Then, to verify whether the survival role of IL-6 and Mcl-1 was specific for our in vitro model or was rather common in other IL-6-positive prostate cancer cell lines, we repeated the previous experiments with CNTO 328 and siRNAs by using the Du145 cell line. Du145 cells derive from a brain metastasis of prostate cancer and release in the medium amounts of IL-6 similar to those from LNCaP-IL-6 þ (Chung et al., 1999) . By measuring the levels of cleaved CK18, we found that the treatment with CNTO 328 was able to significantly increase apoptosis in Du145 cells ( Figure 7a ) and that transfection of Mcl-1 siRNA induced an increase of cleaved CK18 similar to that observed in LNCaP-IL-6 þ cells ( Figure 7b ). Taken together, these data show that Mcl-1 is upregulated in the IL-6-positive cells and is critical for their survival.
Neutralization of endogenous IL-6 by CNTO 328 decreased Mcl-1 protein in LNCaP-IL-6 þ cells As neutralization of endogenous IL-6 and downregulation of Mcl-1 levels each led to sensitization of 17 kDa fragment 15 kDa fragment
Figure 3 Detection of cleaved caspase-3 after treatment with A23187. Western blot analysis showing cleaved caspase-3 and GAPDH protein levels in LNCaP-IL-6À and LNCaP-IL-6 þ cells after treatment with dimethylsulfoxide (DMSO) or A23187. In particular, LNCaP-IL-6À and LNCaP-IL-6 þ cells were plated onto poly-L-lysine hydrobromide-coated 10 cm Petri dishes in the presence of 10% FCS. One day later, medium was removed and 3% CS FCS medium containing 0.5 or 1 mM A23187 or DMSO was added to the cells. After 2 days, the cells were harvested and subjected to Western blot analyses. LNCaP-IL-6 þ cells to apoptosis, we investigated whether the effect of IL-6 on apoptosis is mediated by Mcl-1. To answer this question, we tested whether neutralization of endogenous IL-6 can affect Mcl-1 levels. LNCaP-IL-6 þ and LNCaP-IL-6À cells were therefore exposed to CNTO 328 or equal amounts of hIgG during a period of 6 days. Results from Western analyses show that, in LNCaP-IL-6 þ cells, Mcl-1 levels, normalized to GAPDH, decrease by about 40% in the presence of the anti-IL-6 antibody but not in the presence of control hIgG (Figure 8 ). On the contrary, in LNCaP-IL-6À cells, Mcl-1 protein levels were not affected by the treatment with CNTO 328, thus confirming the specificity of this antibody. A minor but still significant decrease of Mcl-1 protein levels in LNCaP-IL-6 þ was observed also after 4 days of treatment (data not shown). Similar to LNCaP-IL-6 þ , Du145 cells were found to be sensitive to treatment with the antibody in that Mcl-1 levels were decreased by about 40% after 4 days of treatment (data not shown).
CNTO 328 did not cause increased apoptosis in the absence of Mcl-1 To obtain further support for our hypothesis that the IL-6 survival effect is mediated by Mcl-1, we investigated whether reduction of its expression affects the extent of apoptosis induced by CNTO 328. LNCaP-IL-6 þ cells were transfected with 10 nM Mcl-1 or control siRNA in serum-free medium. The next day they were exposed to 10 mg/ml CNTO 328 or hIgG (plus CNTO 328 vehicle). The medium was collected after 2 days and subjected to enzyme-linked immunosorbent assay (ELI-SA) for quantification of the cleaved CK18 ( Figure 9 ). Consistent with our previous data, we found that transfection with Mcl-1 siRNA induced apoptosis of LNCaP-IL-6 þ cells. Also, CNTO 328 was able to induce apoptosis in cells transfected with control siRNA. However, inactivation of IL-6 by CNTO 328 was not effective in inducing additional apoptosis in the absence of Mcl-1. These data demonstrate that the survival role of endogenous IL-6, in LNCaP-IL-6 þ cells, is mediated by the antiapoptotic molecule Mcl-1.
Mcl-1 protein levels decreased after inhibiting ERK1/2 MAPKs We attempted to clarify signaling pathways involved in the increase of Mcl-1 levels caused by IL-6. Data from the literature have demonstrated regulation of Mcl-1 by ERK1/2 MAPKs in other cellular models (Boucher et al., 2000; Selzer et al., 2002; Derouet et al., 2004) . LNCaP-IL-6 þ cells were previously shown to overexpress the activated form of these kinases (i.e. phospho-ERK1/2) (Steiner et al., 2003) . We therefore exposed LNCaP-IL-6À and LNCaP-IL-6 þ cells for 1 day to the MAPK inhibitor PD 98059, at concentrations of 25 and 50 mM. These same concentrations inhibited growth of LNCaP-IL-6 þ cells in a previous study (Steiner et al., 2003) . We found that, despite the efficacy of the inhibitor to decrease the levels of activated ERK1/2 in both cell lines, a decrease of Mcl-1 levels was observed only in LNCaP-IL6 þ cells (Figure 10 ). These data show that the upregulation of Mcl-1 by endogenous IL-6 is mediated, at least partially, by ERK1/2 MAPKs. Conversely, when ERK1/2 signaling pathway was activated by exposing the cells to 10 ng/ ml IL-6 for 8 h, Mcl-1 expression increased significantly in LNCaP-IL-6Àcells ( Figure 11 ). This finding further supports the role of ERK1/2 in mediating the effect of IL-6 on Mcl-1.
Discussion
In this study, we demonstrated the survival role of endogenous IL-6 in a model of late-stage prostate carcinoma represented by LNCaP-IL-6 þ cells. This subline is derived from human prostate LNCaP cells continuously grown in the presence of IL-6. LNCaP-IL-6 þ cells secrete and express the cytokine differently from the control cell, LNCaP-IL-6À, passaged at the same time in the absence of IL-6 . As reported in a previous study, LNCaP-IL-6 þ cells subjected to chronic IL-6 treatment become androgen receptor (AR)-negative (Debes et al., 2005) . In parallel to the loss of AR, LNCaP-IL6 þ cells change morphology resembling the AR-negative and IL-6-positive Du145 and PC3 prostate cancer cells. Owing to the mutual interaction between AR ligands and the IL-6 signaling pathway, we decided to use AR-negative LNCaP-IL-6 þ passages only.
Acquisition of a growth advantage of LNCaP-IL-6 þ cells was related to alterations in expression of cyclindependent kinases, p27 and retinoblastoma, as well as to differences in JAK/STAT3 and MAPKs expression and phosphorylation (Steiner et al., 2003) . Literature reports about either growth-promoting or -inhibiting activities of IL-6 in androgen-sensitive LNCaP cells are available (Okamoto et al., 1997; Lou et al., 2000; Lin et al., 2001) . In our previous studies, proliferation of LNCaP cells was consistently decreased after exposure to IL-6, whereas LNCaP-IL-6 þ cells were not affected by the exogenous cytokine . In this study, we demonstrate that the two cell lines respond differently to IL-6 with regard to apoptosis. Treatment with IL-6 led to the induction of apoptosis in LNCaP parental and control cells but not in LNCaP-IL-6 þ cells. To the best of our knowledge, the only data related to the IL-6 effect on LNCaP cell death are those published very recently by Kawada et al. (2006) . The authors reported that IL-6 alone is not effective in inducing DNA fragmentation or caspase-3-like activities in those cells. However, as in the case of the variable growth response to the cytokine, different experimental conditions and IL-6 concentrations may account for the unequal results. The same authors isolated a new cytokine-resistant cell line, LNCaP-CR, by co-culturing LNCaP cells with WI-38 fibroblasts, in the presence of IL-1b ( Kawada et al., 2006) . Similarly to our findings obtained in LNCaP-IL-6 þ cells, this new cell line was shown to be resistant to the cytotoxic action of IL-6. However, it was not reported whether the cells expressed the cytokine. We hypothesized that the autocrine IL-6 loop established in the selected cells is responsible for the acquisition of resistance to apoptosis. We previously reported that CNTO 328 treatment decreases viability of LNCaP-IL-6 þ cells (Steiner et al., 2006) . We now demonstrate that LNCaP-IL-6 þ cells exposed to CNTO 328 undergo apoptosis. Our results, obtained in the absence of serum, parallel those from Lee et al. (2004) obtained in a different cellular model. The authors showed that LNCaP cells, genetically modified to stably express IL-6, were less sensitive to apoptosis induced by androgen deprivation and that addition of an IL-6 antibody completely abolished the antiapoptotic activity of IL-6. Furthermore, it was shown that neutralization of IL-6 by the murine form of CNTO 328 (CLB-8) induced apoptosis and regression of PC3 prostate tumors xenografted in nude mice .
Cytokines interfere with induction of apoptotic death in different cancer cell lines (Yonish-Rouach et al., 1991; Lotem and Sachs, 1992) . In prostate cancer, neutralization of endogenous IL-6 activity by an anti-IL-6 antibody, IL-6 antisense oligonucleotides or the receptor antagonist Sant7 was shown to increase sensitivity of PC3 and Du145 cells to induction of apoptosis by cytotoxic drugs (Borsellino et al., 1995 (Borsellino et al., , 1999 Pu et al., 2004) . We found that LNCaP-IL-6 þ cells are more resistant than control cells to cytotoxicity of the calcium ionophore A23187. The treatment with the antibody was associated with a tendency to increase A23187-induced apoptosis. From these results, we suggest endogenous IL-6 as a survival factor in our cellular model. Mcl-1, which is highly expressed in hematopoietic cells, is an antiapoptotic member of the Bcl-2 family (Craig, 2002) . In multiple myeloma (MM) cells, in which IL-6 plays a critical role in proliferation and survival, upregulation of Mcl-1 was shown to mediate the antiapoptotic effect of IL-6 (Jourdan et al., 2003) , whereas the downregulation of the gene by antisense technology led to apoptosis (Derenne et al., 2002; Zhang et al., 2002; Le Gouill et al., 2004) . In a study conducted on 12 IL-6-dependent human myeloma cell lines, Mcl-1 was found to be the only Bcl-2 family member (out of ten considered in the study) overexpressed in all the cell lines and regulated by IL-6, thus suggesting Mcl-1 as a major mediator of the survival activity of the cytokine (Craig, 2002; Jourdan et al., 2003; Le Gouill et al., 2004) . Most importantly, overexpression of Mcl-1 in MM and in leukemia in vivo correlates with relapse and shorter survival (Kaufmann et al., 1998; Kitada et al., 1998; Hajnoczky et al., 2003) . Despite the known crucial role of this molecule in protecting cells from apoptosis, in the last decade only a few studies explored Mcl-1 involvement in prostate carcinogenesis (Krajewski et al., 1995; Krajewska et al., 1996; Royuela et al., 2001 Royuela et al., , 2002 . In particular, Krajewska et al. (1996) examined 64 cases of prostate adenocarcinoma with different Gleason scores and 24 cases of PIN. They found that Mcl-1 was expressed in 81% of the tumors, in comparison with only 38% of PIN lesions. The percentage of Mcl-1-positive cells was higher in tumors with Gleason grades 8 to 10 and in metastases than in PIN or lower grade tumors. A second study performed on normal, hyperplastic and carcinomatous human prostates also reported an overexpression of this gene in prostate tumors (Royuela et al., 2001) . Interestingly, Mcl-1 expression was also stimulated by IL-6 in the control cells in conditions in which apoptotic rate increased. We hypothesize that Mcl-1 prosurvival effect is antagonized by other mechanisms in LNCaP-IL-6À cells.
Thus, our in vitro data obtained by utilizing LNCaP-IL-6 þ cells are clinically relevant. They show a mechanism by which Mcl-1 is implicated in prostate carcinogenesis. Mcl-1 seems to have an active role in protection from apoptosis as evidenced in experiments in which siRNA technology was applied. In MM cells, Mcl-1 has been shown to be upregulated by vascular endothelial growth factor (VEGF) (Le Gouill et al., 2004) . Interestingly, LNCaP-IL-6 þ cells secrete significantly higher levels of VEGF than controls . and Mcl-1 are probably common in other IL-6-positive cell lines. Inhibition of Mcl-1 by CNTO 328 in LNCaP-IL-6 þ cells but not in LNCaP-IL-6À cells demonstrates that the difference in the levels of Mcl-1 protein measured in the two cell lines is specifically linked to the endogenous production of IL-6. Recent data published by Raje et al. (2005) show a partial reduction of Mcl-1 expression in MM cells treated with a commercially available neutralizing antibody to human IL-6. In that study, the authors showed that the downregulation of Mcl-1 expression by the small-molecule cyclin-dependent kinase inhibitor seliciclib was associated with inhibition of expression of phospho-STAT3. As a matter of fact, STAT3-binding motifs are present in the promoter of Mcl-1 (Puthier et al., 1999) . Other studies have reported decreased Mcl-1 expression and increased apoptosis after disruption of phospho-STAT3 signaling (Niu et al., 2002; Lee et al., 2004; Nam et al., 2005) . However, we can exclude an involvement of the JAK/ STAT3 pathway in the regulation of Mcl-1 in the present study, as LNCaP-IL-6 þ cells have been previously shown to lack phosphorylated STAT3 (Steiner et al., 2003) .
To uncover signaling pathways responsible for the IL-6-dependent modulation of Mcl-1 in LNCaP-IL-6 þ cells, we turned to ERK1/2 MAPKs activity. We previously showed upregulation of ERK1/2 MAPKs in LNCaP-IL-6 þ cells and growth inhibition following treatment with the specific MAPK inhibitor PD 98059 (Steiner et al., 2003) . We also measured less phospho-ERK1/2 levels in LNCaP-IL-6 þ cells treated with CNTO 328 (Steiner et al., 2006) , demonstrating a direct link between endogenous IL-6 production and ERK1/2 MAPK activation. Our present results demonstrate that ERK1/2 are also important for regulation of the antiapoptotic Mcl-1 protein. Inhibition of ERK1/2 MAPK activity by PD 98059 led to a decrease in the levels of the Mcl-1 protein. Interestingly, the same inhibitor was recently shown to increase docetaxelinduced apoptosis of androgen-independent C-81 LNCaP prostate cancer cells (Zelivianski et al., 2003) . Whether Mcl-1 regulation by the ERK1/2 MAPKs is direct or mediated by other molecules is not addressed in the present paper. However, it should be kept in mind that Mcl-1 regulation may occur at different levels (Domina et al., 2000) . The inability of CNTO 328 to cause additional apoptosis in cells transfected with siRNA against Mcl-1 provides support for the hypothesis that the IL-6 survival effect is mediated by Mcl-1.
In conclusion, our data show that endogenous IL-6 acts as a survival factor in cells representing advanced prostate cancer and that Mcl-1 is an important mediator of its activity. The ERK1/2 MAPKs are specifically involved in this process. CNTO 328 was able to render LNCaP-IL-6 þ cells more sensitive to apoptosis. Taken together with recent data by Wallner et al. (2006) who showed effects of CNTO 328 in the LuCaP 35 xenograft, these results support the concept of anti-IL-6 therapy in human prostate cancer.
Materials and methods

Cell lines
Prostate cancer cells (Du145 and LNCaP) were obtained from ATCC (Rockville, MD, USA). LNCaP sublines LNCaP-IL-6 þ and LNCaP-IL-6À were derived in the presence or absence of IL-6, respectively, as described elsewhere . LNCaP cells were cultured in MCDB-131 supplemented with sodium pyruvate, glucose and 4-(2-hydroxyethyl)-1-piperazineethyl-sulphonic acid (HEPES) buffer, pH 7.2 (Invitrogen, Leek, The Netherlands). Du145, LNCaP-IL-6 þ and LNCaP-IL-6À were cultured in Roswell Park Memorial Institute (RPMI) 1640 (HyClone, Logan, UT, USA). Media were supplemented with 10% FCS and penicillin/streptomycin. LNCaP-IL-6 þ cells were maintained in the presence of 5 ng/ml of IL-6.
Chemicals
Human recombinant IL-6 was from R&D Systems (Minneapolis, MN, USA) and hIgG1 from Dianova (Hamburg, Germany). The calcium ionophore A23187 was purchased from Sigma-Aldrich (Vienna, Austria). CNTO 328 is a product of Centocor (Malvern, PA, USA). Mcl-1 siRNA and silencer negative control no.1 duplexes were generated by Ambion (Cambridgeshire, UK). The MAPK pathway inhibitor PD 98059 was provided by Merck Eurolab (Darmstadt, Germany).
Western blotting
Cells were harvested by scraping or trypsinization. Lysates of cells were obtained by resuspending the pellets in European Organisation for Research and Treatment of Cancer (EORTC) buffer (20 nM NaH 2 PO 4 (pH 7.5), 1 mM ethylenediamine tetracetic acid(EDTA) and 10% glycerol) containing phenylmethylsulfonyl fluoride, sodium fluoride and a cocktail of protease inhibitors (Protease Inhibitor Cocktail Set III, Calbiochem-Novabiochem, San Diego, CA, USA) and phosphatase inhibitors (Phosphatase Inhibitor Cocktail 2, SigmaAldrich). Insoluble portion was removed by centrifugation and protein content was determined by using the Bradford method (Bradford, 1978) . Equal amounts of proteins were resolved into 4-12% Bis-Tris gel (Invitrogen, Leek, The Netherlands) and transferred onto a nitrocellulose membrane (Invitrogen). Membranes were blocked for 1 h at room temperature using Starting Block buffer (Pierce Biotechnology, Rockford, IL, USA) and incubated at 41C overnight in the same buffer after the addition of Tween-20 (0.05%) and primary antibodies. Subsequently, membranes were washed with Tris-buffered saline buffer (TBS-T) and incubated for 1 h at room temperature with fluorescence-labeled secondary antibodies (Molecular Probes, Eugene, OR, USA). Detection and quantifications of bands were performed by using Odyssey Infrared Imaging System (LiCor Biosciences, Lincoln, NE, USA). The following antibodies were used for Western blots: anti-human Mcl-1 antibody (1:500) (Becton Dickinson, Schwechat, Austria), cleaved caspase-3 (Asp175) antibody (1:200) (New England Biolabs, Frankfurt, Germany), antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH) monoclonal antibody IgG1 and anti-actin antibody (1:200 000) (Chemicon, Hampshire, England, UK).
Transient transfections
Cells were plated at low density, in the presence of 10% FCS onto six-(for the detection of Mcl-1 levels by Western analysis) or 24-well (for quantification of apoptotic index) tissue culture plates previously coated with poly-L-lysine hydrobromide (30 mg/ml) (Sigma-Aldrich, Vienna, Austria). One day later, cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. In particular, cells were exposed to the transfection mixture containing Lipofectamine 2000 and Mcl-1 or control siRNA in serum-and antibiotic-free medium. Transfections for Western analyses were carried out in the presence of serum. Final concentration of siRNAs in the well was 10 nM. Mcl-1 siRNA sequence (5 0 -3 0 ) was: GCAAGUGGCAAGAGGAUUAtt.
Analysis of apoptosis by staining for annexin V and fluorescenceactivated cell sorting To determine apoptosis, cells were detached by trypsin, washed with ice-cold phosphate-buffered saline (PBS) and resuspended in 1 ml binding buffer (10 mM HEPES/NaOH (pH 7.4), 1.4 mM NaCl, 2.5 mM CaCl 2 ). A lot of 1 Â 10 5 cells were incubated with 5 ml annexin V-FITC (Pharmingen, San Diego, CA, USA) for 15 min in the dark. Cells were then analysed by flow cytometry (FACS-Calibur, Becton Dickinson) using the CellQuestPRO software (Becton-Dickinson).
Analysis of apoptosis by measuring cleaved CK18 levels As an index of apoptosis, CK18 levels in cell extracts and/or culture supernatants were measured by ELISA using the M30 Apoptosense ELISA kit (Peviva AB, Bromma, Sweden) according to the manufacturer's protocol.
Statistics
The SPSS 12.0 program was used for statistic evaluation and the Mann-Whitney U-test was used for the assessment of statistical significance.
